Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy

Annals of Internal Medicine

Volumn 126, Issue 2, 1997, Pages 133-136

  Harrison, Linda ^a   Johnston, Marilyn ^a   Patricia Massicotte, M ^a   Crowther, Mark ^a   Moffat, Karen ^a   Hirsh, Jack ^a  

^a HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; PROTEIN C; PROTHROMBIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0031018558     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-2-199701150-00006     Document Type: Article

References (18)

1. Quick AJ. The prothrombin time in haemophilia and in obstructive jaundice. J Biol Chem. 1935: 109: 73-4.
2. Hirsh J, Daten JE, Deykin D, Poller L, Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995; 108(4Suppl): 231S-46S.
3. Hellemans J, Vorlat M, Verstraete M. Survival time of prothrombin and factors VII, IX, X after complete synthesis blocking doses of coumarin derivatives. Br J Haematol. 1963; 9: 506-12.
4. Roberts HR, Lechler E, Webster WP, Penick GD. Survival of transfused factor X in patients with Stuart disease. Thrombosis et Diathesis Haemorrhagica. 1965; 13: 305-9.
5. Vigano S, Mannucci PM, Solinas S. Decrease in protein C antigen and formation of an abnormal protein soon after starting oral anticoagulant therapy. Br J Haematol. 1984; 57: 213-20.
6. Okajima K, Koga S, Kaji M, Inoue M, Nakagaki T, Funatsu A, et al. Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects. Thromb Haemost. 1990: 63: 48-53.
7. Hull RD, Hirsh J. Jay R, Carter C England C. Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982; 307: 1676-81.
8. Turpie AG, Gunstensen J, Hirsh J. Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet. 1988; 1: 1242-5.
9. Saour JN, Sieck JO, Mamo LA, Gallus AS. Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med. 1990; 322: 428-32.
10. Altman R, Bouvier J. Gurfinkel E, D'Ortencio O, Manzanel R, de La Fuente L, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg. 1991: 101: 427-31.
11. Landefeld CS, Rosenblatt MW. Bleeding in outpatients treated with warfarin: relation to the prothrombin time and important remediable lesions. Am J Med. 1989; 87: 153-9.
12. Landefeld CS, Goldman L Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989: 87: 144-52.
13. Johnston M, Harrison L, Moffat K, Willan A. Hirsh J. Reliability of the INR for monitoring the induction phase of warfarin: comparison with the prothrombin time ratio. J Lab Clin Med. 1996: 128: 214-7.
14. WHO Expert Committee on Biological Standardization. Thirty-third report. World Health Organ Tech Rep Ser. 19S3; 687: 81-105.
15. Bigg R. Human Blood Coagulation. London: Blackwell Scientific; 1972: 614.
16. Griffin JH, Evatt B, Zimmerman TS. Kleiss AJ, Wideman C. Deficiency of protein C in congenital thrombotic disease. J Clin Invest. 1981: 68: 1370-3.
17. Wessler S, Gitel SN. Warfarin. From bedside to bench. N Engl J Wed. 1984; 311: 645-52.
18. Zivelin A, Rao LV, Rapaport SI. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. J Clin Invest. 1993; 92: 2131-40.